Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H9NO2.ClH |
| Molecular Weight | 139.581 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)CC(O)=O
InChI
InChIKey=FKASAVXZZLJTNX-UHFFFAOYSA-N
InChI=1S/C4H9NO2.ClH/c1-5(2)3-4(6)7;/h3H2,1-2H3,(H,6,7);1H
| Molecular Formula | C4H9NO2 |
| Molecular Weight | 103.1198 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
N,N-dimethylglycine or dimethylglycine (DMG) is an amino acid derivative found in the cells of all plants and animals and can be obtained in the diet in small amounts from grains and meat. The human body produces DMG when metabolizing choline into glycine. DMG has been found acting at glycine binding site of the N-methyl-d-aspartate receptor (NMDAR). DMG has had wide acceptance as a nonfuel nutrient; presumably it enhances oxygen utilization by tissue and complexes free radicals. There were published studies, which have shown little to no difference between DMG treatment and placebo in autism spectrum disorders and the same no effect was observed in case of investigated DMG for epilepsy. This compound was also suggested to use to improve the athletic performance enhancer, but this usage was ineffective as well.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cloning of dimethylglycine dehydrogenase and a new human inborn error of metabolism, dimethylglycine dehydrogenase deficiency. | 2001 Apr |
|
| Investigations into biochemical changes due to diurnal variation and estrus cycle in female rats using high-resolution (1)H NMR spectroscopy of urine and pattern recognition. | 2001 Aug 15 |
|
| Homocysteine metabolism in children with Down syndrome: in vitro modulation. | 2001 Jul |
|
| Organization of the genes involved in dimethylglycine and sarcosine degradation in Arthrobacter spp.: implications for glycine betaine catabolism. | 2001 Jun |
|
| Effectiveness of N,N-dimethylglycine in autism and pervasive developmental disorder. | 2001 Mar |
|
| Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy. | 2001 Nov |
|
| Testosterone 17beta-N,N-dimethylglycinate hydrochloride: A prodrug with a potential for nasal delivery of testosterone. | 2002 Mar |
|
| A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055. | 2003 Dec 4 |
|
| Isolation and functional characterization of N-methyltransferases that catalyze betaine synthesis from glycine in a halotolerant photosynthetic organism Aphanothece halophytica. | 2003 Feb 14 |
|
| The osmoprotectants glycine and its methyl derivatives prevent the thermal inactivation of protective antigen of Bacillus anthracis. | 2004 Apr 2 |
|
| Mammalian electron transferring flavoprotein.flavoprotein dehydrogenase complexes observed by microelectrospray ionization-mass spectrometry and surface plasmon resonance. | 2004 Apr 2 |
|
| A novel gamma-N-methylaminobutyrate demethylating oxidase involved in catabolism of the tobacco alkaloid nicotine by Arthrobacter nicotinovorans pAO1. | 2004 Dec |
|
| Betaine: a key modulator of one-carbon metabolism and homocysteine status. | 2005 |
|
| Di-mu-chloro-1:2kappa2Cl;3:4kappa2Cl-hexachloro-1kappa3Cl,4kappa3Cl-tetra-mu-dimethylglycine-2:3kappa8O:O'-tetracopper(II). | 2005 Aug |
|
| Gas-phase structure of N,N-dimethylglycine. | 2005 Aug 12 |
|
| Stabilization of non-productive conformations underpins rapid electron transfer to electron-transferring flavoprotein. | 2005 Aug 26 |
|
| NMR spectroscopic-based metabonomic investigation on the acute biochemical effects induced by Ce(NO3)3 in rats. | 2005 Nov |
|
| Critical active-site residues identified by site-directed mutagenesis in Pseudomonas aeruginosa phosphorylcholine phosphatase, a new member of the haloacid dehalogenases hydrolase superfamily. | 2006 Dec |
|
| Effects of substrate and potassium on the betaine-synthesizing enzyme glycine sarcosine dimethylglycine N-methyltransferase from a halophilic methanoarchaeon Methanohalophilus portucalensis. | 2006 Dec |
|
| In silico experimentation with a model of hepatic mitochondrial folate metabolism. | 2006 Dec 6 |
|
| Treatment for mitochondrial disorders. | 2006 Jan 25 |
|
| Mechanism of FAD reduction and role of active site residues His-225 and Tyr-259 in Arthrobacter globiformis dimethylglycine oxidase: analysis of mutant structure and catalytic function. | 2006 Sep 19 |
|
| Characterization of oxysterols by electrospray ionization tandem mass spectrometry after one-step derivatization with dimethylglycine. | 2007 |
|
| Beyond lipids, pharmacological PPARalpha activation has important effects on amino acid metabolism as studied in the rat. | 2007 Apr |
|
| Structure-activity and high-content imaging analyses of novel tubulysins. | 2007 Aug |
|
| The salt-induced ABC transporter Ota of the methanogenic archaeon Methanosarcina mazei Gö1 is a glycine betaine transporter. | 2007 Dec |
|
| Sex differences in the control of plasma concentrations and urinary excretion of glycine betaine in patients attending a lipid disorders clinic. | 2007 Nov |
Patents
Sample Use Guides
epilepsy: Dosage was 300 mg/day for the first 14 days and then 600 mg/day up to 28 days
Route of Administration:
Oral
It was investigated the effects of N, N-Dimethylglycine (DMG) on the development of in vitro produced (IVP) bovine embryos. IVP embryos were obtained by in vitro fertilization of in vitro matured oocytes for 6 h. In Experiment 1, IVP embryos were cultured in mSOFaa supplemented with bovine serum albumin but without glucose (SOF1) for 4 days, transferred to mSOFaa (with 5% fetal bovine serum and 1.5 mM glucose; SOF2) supplemented with 0 (control), 0.1,1 or 10 microM DMG and cultured for an additional 7 days (11 days in total) to assess their development in vitro. When cultured in the medium with 0.1 microM DMG, a significantly higher number of IVP embryos developed to the blastocyst and hatched blastocyst stages (40.3 and 40.8%, respectively) compared with the other groups (18.7-31.0% and 15.0-28.7%, respectively; P<0.05, analysis of variance). In Experiment 2, IVP embryos were cultured in SOF1 with or without 0.1 microM DMG for 4 days, transferred to SOF2 with or without 0.1 microM DMG and further cultured as in Experiment 1; DMG was added to either SOF1 or SOF2 and to both of them to assess its exposure effects on embryo development. When cultured continuously with DMG for 11 days, significantly higher rates of IVP embryos developed into blastocyst and hatched blastocyst stages (39.0 and 47.7%, respectively) compared with the other groups (31.0-32.2% and 29.5-31.0%, respectively; P<0.05). In Experiment 3, we examined developmental speed of IVP embryos cultured with or without addition of 0.1 microM DMG to IVC medium after 7 days of IVC.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:04:54 GMT 2023
by
admin
on
Fri Dec 15 18:04:54 GMT 2023
|
| Record UNII |
YXK75EAE92
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1921876
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
m4539
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
2491-06-7
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
219-648-2
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
DTXSID1062463
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
75605
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
YXK75EAE92
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY | |||
|
YXK75EAE92
Created by
admin on Fri Dec 15 18:04:54 GMT 2023 , Edited by admin on Fri Dec 15 18:04:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
